Conatus Pharmaceuticals (CNAT) Hits New 1-Year Low After Analyst Downgrade
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares hit a new 52-week low during mid-day trading on Thursday after SunTrust Banks lowered their price target on the stock to $12.00. SunTrust Banks currently has a buy rating on the stock. Conatus Pharmaceuticals traded as low as $1.80 and last traded at $2.16, with a volume of 131041 shares. The stock had previously closed at $4.50.
A number of other analysts have also recently weighed in on CNAT. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, November 5th. Finally, Stifel Nicolaus cut shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $11.12.
Hedge funds have recently added to or reduced their stakes in the stock. Alambic Investment Management L.P. boosted its stake in Conatus Pharmaceuticals by 207.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 178,461 shares in the last quarter. Bank of America Corp DE boosted its stake in Conatus Pharmaceuticals by 75.7% in the 2nd quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 60,604 shares in the last quarter. Paloma Partners Management Co purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $547,000. Artal Group S.A. purchased a new position in Conatus Pharmaceuticals during the 3rd quarter worth approximately $2,900,000. Finally, MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $154,000. Institutional investors own 31.93% of the company’s stock.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $9.70 million. On average, analysts anticipate that Conatus Pharmaceuticals Inc will post -0.6 EPS for the current year.
Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.